NasdaqGS - Nasdaq Real Time Price • USD
Neumora Therapeutics, Inc. (NMRA)
As of 11:31 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | -0.37 | -0.39 | -1.48 | -1.57 |
| Low Estimate | -0.41 | -0.44 | -1.64 | -1.75 |
| High Estimate | -0.34 | -0.36 | -1.38 | -1.41 |
| Year Ago EPS | -- | -1.14 | -3.63 | -1.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | |
|---|---|---|---|---|
| EPS Est. | -- | -0.36 | -0.55 | -0.34 |
| EPS Actual | -- | -1.14 | -0.71 | -0.34 |
| Difference | -- | -0.78 | -0.16 | 0 |
| Surprise % | -- | -216.70% | -29.10% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.39 | -1.48 | -1.57 |
| 7 Days Ago | -0.37 | -0.4 | -1.5 | -1.63 |
| 30 Days Ago | -0.37 | -0.4 | -1.5 | -1.63 |
| 60 Days Ago | -0.38 | -0.41 | -1.52 | -1.66 |
| 90 Days Ago | -0.68 | -0.65 | -2.09 | -1.54 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 3 | 3 | 1 |
| Up Last 30 Days | 1 | 3 | 3 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | NMRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 8.30% |
| Next Qtr. | 65.80% | -- | -- | 11.90% |
| Current Year | 59.20% | -- | -- | 5.60% |
| Next Year | -6.10% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 11.05% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | RBC Capital: Outperform to Outperform | 3/28/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/18/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 3/8/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 11/8/2023 |
| Initiated | JP Morgan: Overweight | 10/10/2023 |
| Initiated | B of A Securities: Buy | 10/10/2023 |
Related Tickers
SLRN Acelyrin, Inc.
4.8800
+4.05%
LXEO Lexeo Therapeutics, Inc.
13.93
+2.73%
CRGX CARGO Therapeutics, Inc.
20.02
+2.61%
MLYS Mineralys Therapeutics, Inc.
13.02
+0.70%
DNLI Denali Therapeutics Inc.
19.71
+2.13%
BOLD Boundless Bio, Inc.
9.49
-0.32%
CNTA Centessa Pharmaceuticals plc
9.18
+3.96%
KYTX Kyverna Therapeutics, Inc.
15.06
+2.94%
REPL Replimune Group, Inc.
6.72
+1.97%
PHVS Pharvaris N.V.
21.32
+0.71%